Search results
Results from the WOW.Com Content Network
R1 - cancer cells present microscopically at the primary tumour site. R2 - Macroscopic residual tumour at primary cancer site or regional lymph nodes. It does not include metastatic disease identified but not sampled at the time of surgery. The Margin Status following tumour resection (AJCC 8th Edition): Negative margin: No tumour at the margin.
There are several rare sub-types of invasive carcinoma NST including pleomorphic carcinoma, carcinoma with osteoclast-like stromal giant cells, carcinoma with choriocarcinomatous features, and carcinoma with melanotic features. [1] Invasive breast carcinomas are most common in White women, followed by Black and Hispanic women. Black women tend ...
Response evaluation criteria in solid tumors (RECIST) is a set of published rules that define when tumors in cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progress") during treatment.
Minimal residual disease (MRD), also known as Molecular residual disease, is the name given to small numbers of cancer cells that remain in a person either during or after treatment when the patient is in remission (no symptoms or signs of disease). Sensitive molecular tests are either in development or available to test for MRD.
Positive prognostic factors – those indicating better chances of survival – include no residual disease after surgery (stage III/IV), complete macroscopic resection (stage IV), BRCA2 mutations, young age (under 45 years), nonserous type, low histologic grade, early stage, co-occurrence with endometrial cancer, and low CA-125 levels.
Ductal carcinoma in situ (DCIS), also known as intraductal carcinoma, is a pre-cancerous or non-invasive cancerous lesion of the breast. [ 1 ] [ 2 ] DCIS is classified as Stage 0. [ 3 ] It rarely produces symptoms or a breast lump that can be felt, typically being detected through screening mammography .
Cancer of unknown primary origin (CUP) is a cancer that is determined to be at the metastatic stage at the time of diagnosis, but a primary tumor cannot be identified. A diagnosis of CUP requires a clinical picture consistent with metastatic disease and one or more biopsy results inconsistent with a tumor cancer.
Some cases of EIN are first detected as residual premalignant disease in women who already have carcinoma, whereas other EIN lesions disappear entirely and never lead to cancer. For this reason, treatment benefits and risks must be individualized for each patient under the guidance of an experienced physician.